Abstract: A position sensor comprises a first part having several electrically conductive elements, a second part having an electrical conductor, and holding means holding the first part and the second part together with the conductive elements and the conductor being spaced apart and permitting relative movement between the conductive elements and the conductor. Included is a signal generator for generating and supplying different electrical signals to one of the first part and the second part for reception in a contactless manner by the other of the first part and the second part with a magnitude that is dependent upon the relative position between the conductive elements and the conductor. There is also a signal detector connected to the other of the first part and the second part for differentiating the electrical signals received thereby to determine the relative position between the conductive elements and the conductor.

Abstract: A vascular filter for capturing and breaking apart particles in the blood. The vascular filter includes a filter body and an agitation member disposed within the filter body. Movement of the agitation member acts on particles trapped within the filter body for enhancing the dissolution of the particles, thereby reducing the likelihood of filter occlusion and improving the flow of blood through the vessel. The vascular filter is preferably collapsible for percutaneous delivery to a treatment site. The agitation member is preferably rotatably coupled to the filter body and a flow receiving member is provided for causing the agitation member to rotate. A clutch mechanism may be provided such that the agitation member only rotates when a particle, such as a blood clot, is trapped within the filter body.

Abstract: A pharmaceutical formulation suitable for multi-dose administration comprising endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxanide hydrochloride, a preservative selected from the group consisting of alkyl paraben and phenol, and a buffer selected from the group consisting of acetate and phosphate buffers is disclosed.

Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine, including promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more non-ionic surfactants and at least one amino acid and/or one polyol prior to administration to an animal such as a mammal.

Abstract: An electrical power supply system firstly includes a power cable electrically connected to a power source. The power cable has a power line and a first conductor; the first conductor is isolated from the power line and acts as a sensing line. The power cable also has a second conductor and the second conductor is isolated from the sensing line and acts as a neutral line; the power line, the sensing line and the neutral line are electrically connected to the power source. The system further includes an arc fault circuit interrupter including a sensing circuit in electrical connection with the sensing line for detecting an arc fault and a voltage source being in electrical connection with the sensing line. The voltage of the voltage source is designed to be below the hazardous voltage according to the electrical safety rules.

Abstract: The invention relates to an ITO heater for a liquid crystal display, typically a DSTN display which comprises an active liquid crystal cell for optical modulation, characterized by a dummy cell adapted for optical compensation comprising two substrates with liquid crystal therebetween, by a heater, the heater comprising a transparent conductive layer applied to one of the substrates, and by the dummy cell further comprising electrically conductive spacing means for simultaneously maintaining a desired cell gap and equalizing the electrical potential between the two substrates.

Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.

Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.

Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.

Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.

Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine, including promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more non-ionic surfactants and at least one amino acid and/or one polyol prior to administration to an animal such as a mammal.

Abstract: The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Abstract: Sterile pharmaceutical compositions parenteral administration containing propofol in an oil-in-water emulsion additionally containing an amount of the preservative tromethamine sufficient to prevent signficant growth of microorganisms for at least 24 hours after extrinsic contamination.

Abstract: The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Abstract: Stable aqueous solution formulations containing alfa-interferon type interferon, e.g., interferon alfa-2a and interferon alfa-2b, a buffer to maintain the pH in the range of 4.5-7.1, polysorbate 80 as a stabilizer, edetate disodium as a chelating agent, sodium chloride as a tonicity agent, and m-cresol as an antimicrobial preservative and which maintain high chemical, physical and biological stability of the alfa-type interferon for an extended storage period of at least 24 months are disclosed.

Abstract: A method of making a combined printed circuit board having a hollow portion or a through hole and an integrated circuit driver, wherein an external surface of the board and the driver is substantially planar. The method comprises steps of mounting the driver in the hollow portion, providing means temporarily for holding the driver in the hollow portion, encapsulating resin the driver with resin, and then removing the temporarily holding means.

Abstract: Process for making stable aqueous solution formulations containing alfa-type interferon, e.g., interferon alfa-2a and interferon alfa-2b, a buffer to maintain the pH in the range of 4.5-7.1, polysorbate 80 as a stabilizer, edetate disodium as a chelating agent, sodium chloride as a tonicity agent, and m-cresol as an antimicrobial preservative and which maintain high chemical, physical and biological stability of the alfa interferon for an extended storage period of at least 24 months are disclosed.

Abstract: A process for preparing aqueous parenteral compositions of drugs which are weak bases and are only slightly soluble in water is disclosed. Aqueous parenteral compositions of the antifungal agent (.+-.) (2R*, 3R*)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2 -ol are also disclosed.

Abstract: Buffered aqueous solution of thimerosal wherein the buffer is citric acid and sodium citrate having a pH between 3.5 and 7.

Abstract: Disclosed is a kit for preparing a lyophilized alpha interferon gel formulation suitable for topical administration.